Search filters

List of works by Filippo Pietrantonio

A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer

scientific article published on 4 September 2015

A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the 'BRAF BeCool' study

scientific article published on 19 July 2019

ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer.

scientific article published in December 2017

Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer.

scientific article published on 8 December 2016

Activity of temozolomide in patients with advanced chemorefractory colorectal cancer and MGMT promoter methylation.

scientific article

Adjuvant chemotherapy for gastric cancer: current evidence and future challenges.

scientific article published on April 2014

Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial

scientific article published on 29 March 2019

BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

scientific article published on 7 July 2015

BRAF in metastatic colorectal cancer: the future starts now.

scientific article

BRAF-mutated metastatic colorectal cancer between past and future.

scientific article published on 10 September 2015

Bax expression is predictive of favorable clinical outcome in chemonaive advanced gastric cancer patients treated with capecitabine, oxaliplatin, and irinotecan regimen

scientific article

Benefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study

scientific article published on 08 March 2019

Bevacizumab treatment in the elderly patient with metastatic colorectal cancer

scientific article

Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: Pitfalls and helpful tricks in a review for clinicians.

scientific article published on 25 April 2015

Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study.

scientific article published on 5 December 2017

Bright-field in situ hybridization detects gene alterations and viral infections useful for personalized management of cancer patients.

scientific article published on 12 February 2018

CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer

scientific article published on 02 September 2019

Capecitabine, oxaliplatin and irinotecan in combination, with bevacizumab (COI-B regimen) as first-line treatment of patients with advanced colorectal cancer. An Italian Trials of Medical Oncology phase II study

article

Chemotherapy or targeted therapy as second-line treatment of advanced gastric cancer. A systematic review and meta-analysis of published studies

scientific article

Chemotherapy-induced ileal crypt apoptosis and the ileal microbiome shape immunosurveillance and prognosis of proximal colon cancer

scientific article published on 25 May 2020

Chronomodulated Capecitabine and Adjuvant Radiation in Intermediate-risk to High-risk Rectal Cancer

scientific article published on 01 December 2014

Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens

scientific article

Circulating tumor cells as a longitudinal biomarker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab

scientific article

Class 1, 2, and 3 BRAF-Mutated Metastatic Colorectal Cancer: A Detailed Clinical, Pathologic, and Molecular Characterization

scientific article published on 09 April 2019

Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable.

scientific article

Clinical retrospective analysis of erlotinib in the treatment of elderly patients with advanced non-small cell lung cancer.

scientific article

Combination or single-agent chemotherapy as adjuvant treatment of gastric cancer: A systematic review and meta-analysis of published trials

scientific article published on 9 October 2015

Continuing single-agent bevacizumab as maintenance therapy after induction XELOX (or FOLFOX) plus bevacizumab in first-line treatment of metastatic colorectal cancer

scientific article published on 16 October 2012

Correction to: Clinical Surveillance After Macroscopically Complete Surgery for Low-Grade Appendiceal Mucinous Neoplasms (LAMN) with or Without Limited Peritoneal Spread: Long-Term Results in a Prospective Series.

scientific article

DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan

scientific article

DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients

scientific article published on 06 February 2019

Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials.

scientific article published on 13 March 2018

Digital PCR assessment of MGMT promoter methylation coupled with reduced protein expression optimises prediction of response to alkylating agents in metastatic colorectal cancer patients.

scientific article published on 16 December 2016

Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer.

scientific article published on 25 June 2015

Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal Cancer

scientific article published on 4 November 2015

Early tumour shrinkage as a prognostic factor and surrogate end-point in colorectal cancer: a systematic review and pooled-analysis

scientific article published on 17 March 2015

Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden

scientific article published on 05 May 2020

Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest.

scientific article published on 13 December 2016

Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer

scientific article

Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram

article

FOLFIRI with cetuximab or bevacizumab: FIRE-3

scientific article published on 24 November 2014

FOLFOX-4 chemotherapy for patients with unresectable or relapsed peritoneal pseudomyxoma

scientific article

First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis

scientific article published on 5 June 2015

From biology to clinical experience: evolution in the knowledge of neuroendocrine tumours

GNAS mutations as prognostic biomarker in patients with relapsed peritoneal pseudomyxoma receiving metronomic capecitabine and bevacizumab: a clinical and translational study

scientific article published on 6 May 2016

Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status

scientific article

Gastric cancer: Translating novels concepts into clinical practice

scientific article published on 14 August 2019

Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM)

article

Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies

scientific article published on 25 July 2018

HER2 loss in HER2-positive gastric or gastroesophageal cancer after trastuzumab therapy: Implication for further clinical research.

scientific article published on 31 August 2016

Hepatic colorectal cancer metastases showing a distinctive pattern of pathological response after metronomic capecitabine and bevacizumab

scientific article published on 21 January 2012

Heterogeneity of Acquired Resistance to Anti-EGFR Monoclonal Antibodies in Patients with Metastatic Colorectal Cancer.

scientific article published on 25 October 2016

How the lab is changing our view of colorectal cancer

scientific article published on 20 September 2016

Hyperthermic Intraperitoneal Chemotherapy (HIPEC) at the Time of Primary Curative Surgery in Patients with Colorectal Cancer at High Risk for Metachronous Peritoneal Metastases

scientific article

IL-8 and eNOS polymorphisms predict bevacizumab-based first line treatment outcomes in RAS mutant metastatic colorectal cancer patients

scientific article published on 25 January 2017

Impact of Pre-Analytical Factors on MSI Test Accuracy in Mucinous Colorectal Adenocarcinoma: A Multi-Assay Concordance Study

scientific article published on 02 September 2020

Impact on survival of timing and duration of adjuvant chemotherapy in radically resected gastric cancer

scientific article published on 30 March 2016

Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth.

scientific article published on 29 November 2017

Incidence and relative risk of grade 3 and 4 diarrhoea in patients treated with capecitabine or 5-fluorouracil: a meta-analysis of published trials

scientific article

Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies

scientific article published on 30 August 2018

Innovative therapy, monoclonal antibodies, and beyond: Highlights from the eighth annual meeting

scientific article published on 30 October 2018

Intestinal microbiota influences clinical outcome and side effects of early breast cancer treatment

scientific article published on 07 May 2021

Intratumoral Transcriptome Heterogeneity Is Associated With Patient Prognosis and Sidedness in Patients With Colorectal Cancer Treated With Anti-EGFR Therapy From the CO.20 Trial

scientific article published on 29 September 2020

Investigating the concordance in molecular subtypes of primary colorectal tumors and their matched synchronous liver metastasis

scientific article published on 09 April 2020

Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?

scientific article published on 04 February 2019

Is the standardized uptake value of FDG-PET/CT predictive of pathological complete response in locally advanced rectal cancer treated with capecitabine-based neoadjuvant chemoradiation?

scientific article published on 15 January 2013

Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients.

scientific article published on 21 November 2012

Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous Component

scientific article published on 07 March 2019

Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT.

scientific article published on 3 July 2013

LightSNiP assay is a good strategy for pharmacogenetics test

scientific article published on 2 June 2015

Location of Primary Tumor and Benefit From Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer.

scientific article published on 5 July 2016

MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.

scientific article

Maintenance Therapy With Panitumumab Alone vs Panitumumab Plus Fluorouracil-Leucovorin in Patients With RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial

scientific article published on 03 July 2019

Management of advanced genitourinary tumors

scientific article published in March 2012

Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma Peritonei

scientific article published on 01 April 2019

MicroRNAs in non-small cell lung cancer: current status and future therapeutic promises.

scientific article published on January 2014

Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study

scientific article published on 25 September 2017

New perspectives in advanced genitourinary malignancies

scientific article published on March 2012

Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer

scientific article published on 11 April 2015

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy

scientific article published in February 2018

Outcomes of Advanced Gastric Cancer Patients Treated with at Least Three Lines of Systemic Chemotherapy.

scientific article published on 31 August 2017

Panitumumab-based maintenance after oxaliplatin discontinuation in metastatic colorectal cancer: A retrospective analysis of two randomised trials

scientific article published on 24 January 2019

Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases

article

Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases

scientific article published on 24 November 2018

Perioperative Triplet Chemotherapy and Cetuximab in Patients With RAS Wild Type High Recurrence Risk or Borderline Resectable Colorectal Cancer Liver Metastases

scientific article published on 06 October 2016

Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition

scientific article published on 14 February 2019

Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.

scientific article

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis

scientific article

Predictive testing for DPD deficiency in a patient with familial history of fluoropyrimidine-associated toxicity

scientific article published on 24 February 2014

Preoperative Capecitabine, Oxaliplatin, and Irinotecan in Resectable Gastric or Gastroesophageal Junction Cancer: Pathological Response as Primary Endpoint and FDG-PET Predictions

scientific article published on 8 September 2017

Prognostic Impact of Microsatellite Instability in Asian Gastric Cancer Patients Enrolled in the ARTIST Trial

scientific article published on 02 May 2019

Prognostic factors in 868 advanced gastric cancer patients treated with second-line chemotherapy in the real world.

scientific article published on 27 December 2016

Prognostic impact of ATM mutations in patients with metastatic colorectal cancer

scientific article published on 27 February 2019

Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis.

scientific article

Progress in treatments for colorectal cancer peritoneal metastases during the years 2010-2015. A systematic review

scientific article published on 22 January 2016

Pseudomyxoma Peritonei of Extra-Appendiceal Origin: A Comparative Study.

scientific article published on 28 June 2016

RET fusions in a small subset of advanced colorectal cancers at risk of being neglected

scientific article published on 10 March 2018

RNF43 mutations predict response to anti-BRAF/EGFR combinatory therapies in BRAFV600E metastatic colorectal cancer

scientific article published in 2022

Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer: Real-World Data from the RAMoss Study

scientific article published on 27 March 2018

Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial

scientific article published on 01 March 2019

Refining the selection of patients with metastatic colorectal cancer for treatment with temozolomide using proteomic analysis of O6-methylguanine-DNA-methyltransferase

scientific article published on 19 December 2018

Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.

scientific article

Reply to FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS-mutated tumours in the randomised German AIO study KRK-0306

scientific article published on 08 August 2012

Reply to the letter to the editor 'new life for retrospective study in the precision oncology era' by Orlandi et al.

scientific article

Role of BAX for outcome prediction in gastrointestinal malignancies.

scientific article published on 23 May 2013

Role of MGMT as biomarker in colorectal cancer

scientific article

Role of cMET in the development and progression of colorectal cancer

scientific article published on 03 September 2013

Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer

scientific article published on February 2011

Second-line angiogenesis inhibition in metastatic colorectal cancer patients: Straightforward or overcrowded?

scientific article published on 12 February 2016

Selecting patients for gastrectomy in metastatic esophago-gastric cancer: clinics and pathology are not enough.

scientific article published on 4 October 2017

Single agent panitumumab in KRAS wild-type metastatic colorectal cancer patients following cetuximab-based regimens: Clinical outcome and biomarkers of efficacy

scientific article published on 04 September 2013

Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope

scientific article

Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis

scientific article published on 15 November 2016

TP53 mutations in advanced colorectal cancer: the dark side of the moon.

scientific article published on 07 June 2014

TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.

scientific article

TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable and wild-type metastatic colorectal cancer

scientific article published on 09 July 2018

Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions

scientific article published on 21 November 2016

Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation

scientific article published on 01 August 2018

The Landscape of Actionable Gene Fusions in Colorectal Cancer

scientific article published on 25 October 2019

The PANDA study: a randomized phase II study of first-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS and BRAF wild-type elderly metastatic colorectal cancer patients.

scientific article published on 25 January 2018

The landscape of d16HER2 splice variant expression across HER2-positive cancers

scientific article published on 05 March 2019

Toward the molecular dissection of peritoneal pseudomyxoma.

scientific article published in November 2016

TremelImumab and Durvalumab Combination for the Non-OperatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study

scientific article published in 2021

Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program

scientific article published on 08 May 2018

Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase

scientific article published on 21 April 2015

Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial

scientific article published on 06 October 2020

Variant alleles in factor V, prothrombin, plasminogen activator inhibitor-1, methylenetetrahydrofolate reductase and risk of thromboembolism in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab.

scientific article published on 22 March 2016

Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study.

scientific article published on 10 August 2017

Weighing the prognostic role of hyponatremia in hospitalized patients with metastatic solid tumors: the HYPNOSIS study

scientific article published on 10 September 2019

[Second-line treatment with FOLFIRI plus aflibercept in a patient with right-sided, BRAF mutated metastatic colon cancer.]

scientific article published on 01 November 2018

miR-205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling.

scientific article published in September 2018

Paulina is supported by:

About Paulina

Help